Table 1.
Patient characteristics
| Variable | n | % | |
|---|---|---|---|
| Age | Median (Min-Max) | 49 (24–83) | |
| Menopausal status | Post- | 92 | 51.4 |
| Pre- | 87 | 48.6 | |
| Surgical status | MRM | 114 | 63.7 |
| BCS | 65 | 36.3 | |
| Hormone-receptor status | Positive | 152 | 80.4 |
| HER2-status | Positive | 30 | 17.3 |
| TNCB | Yes | 9 | 5.0 |
| Histology | IDC | 165 | 92.2 |
| ILC | 14 | 7.8 | |
| Stage | II | 81 | 45.3 |
| III | 98 | 54.7 | |
| Grade | I+II | 125 | 69.8 |
| III | 54 | 30.2 | |
| Perineural invasion | Negative | 135 | 75.4 |
| Positive | 44 | 24.6 | |
| Lymphovascular invasion | Negative | 73 | 40.8 |
| Positive | 106 | 59.2 | |
| pT-stage | T1–2 | 134 | 74.9 |
| T3–4 | 45 | 25.1 | |
| Lymph node removed | Median (Min-Max) | 15 (3–48) | |
| Metastatic lymph node | Median (Min-Max) | 3 (1–29) | |
| pN- stage | 1–3 | 91 | 50.8 |
| 4–9 | 60 | 33.5 | |
| ≥10 | 28 | 15.6 | |
| LNR | <0.21 | 90 | 50.3 |
| 0.21–0.65 | 62 | 34.6 | |
| >0.65 | 27 | 15.1 | |
| Margin status | Positive | 9 | 5.0 |
| Adjuvant Chemotherapy | Doxorubicin | 38 | 21.2 |
| Doxorubicin +Taxane | 137 | 76.5 | |
| Taxane | 4 | 2.2 | |
| Adjuvant trastuzumab | Yes | 30 | 16.8 |
| Adjuvant hormonotherapy | Yes | 152 | 84.9 |
| Tamoxifen | 76 | 50.0 | |
| Aromatase inhibitors | 76 | 50.0 | |
| Adjuvant Radiotherapy | Yes | 171 | 95.5 |
| Recurrence and localization | Yes | 32 | 17.9 |
| locoregional | 3 | 9.4 | |
| Bone | 20 | 62.5 | |
| Liver | 3 | 9.4 | |
| Lung | 4 | 12.5 | |
| Brain | 2 | 6.3 | |
| Final status | Exitus | 8 | 4.5 |
| Alive | 171 | 95.5 |
BCS: Breast-conserving Surgery; HER2: Human Epidermal Growth Factor Receptor 2; ILC: Invasive Lobular Carcinoma; IDC: Invasive Ductal Carcinoma; LNR: Lymph Node Ratio; MRM: Modified Radical Mastectomy; pT: Pathologic Tumor Stage; pN: Pathologic Lymph Node Stage; SD: Standard Deviation; TNBC: Triple-Negative Breast Cancer